Targets › ERBB2
165 programs from 118 companies in 647 trials: 348 Phase 2, 162 Phase 1, 122 Phase 3, 15 Phase 4; Oncology, Other, Genitourinary; next expected readout Nov 2026.
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. (UniProt, P04626)
Open in Phaseline: the race on ERBB2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Michael Hopp | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 4 | Non-squamous NSCLC | Dec 2026 |
| AstraZeneca | Trastuzumab deruxtecan Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor | ERBB2, TOP1 | Phase 4 | BREAST CANCER; Advanced or Metastatic Breast Cancer; Breast Neoplasms; Breast Cancer; HER2-positive; Metastatic … | Dec 2026 |
| Fudan University | DS8201 Anti-HER2 antibody-drug conjugate | ERBB2 | Phase 4 | HER2-negative Breast Cancer | Jan 2027 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Inetetamab Anti-HER2 monoclonal antibody | ERBB2 | Phase 4 | Metastatic Breast Cancer | Dec 2027 |
| Institut Claudius Regaud | Trastuzumab-Deruxtecan (T-DXd) anti-HER2 antibody-drug conjugate with topoisomerase I inhibitor payload (DXd) | ERBB2 | Phase 4 | Locally Advanced or Metastatic Breast Cancers | Oct 2029 |
| Psoriasis Treatment Center of Central New Jersey | Duobrii Dual EGFR and ErbB2 inhibitor topical cream | EGFR, ERBB2 | Phase 4 | Psoriasis | – |
| Shanghai JMT-Bio | Kn-026 (KN026) Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Early or Locally Advanced HER2-positive Breast Cancer; First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer; Resectable HER2-positive Breast Cancer; Stomach Cancer … | Nov 2026 |
| Jiangsu HengRui Medicine | SHR-A1811 for Injection HER2-targeted antibody-drug conjugate | ERBB2 | Phase 3 | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane; Non-Small Cell Lung Cancer With HER2- Mutations; Ovarian Cancer; HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma … | Nov 2026 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB2102 for injection HER2-targeting antibody-drug conjugate (ADC) with dual epitope targeting (ECD2 and ECD4) | ERBB2 | Phase 3 | HER2-positive Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Gynecological Tumors … | Nov 2026 |
| Sichuan Kelun-Biotech Biopharmaceutical | Trastuzumab Botidotin (A166) Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin inhibitor | ERBB2, Tubulin | Phase 3 | HER2-positive Breast Cancer; Her 2 Positive Breast Cancer | Nov 2026 |
| RemeGen | Disitamab Vedotin Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin disrupting agent | ERBB2, Tubulin | Phase 3 | Urothelial Carcinoma; Breast Cancer; Gastric Carcinoma; Gastric Cancer … | Dec 2026 |
| Boehringer Ingelheim | Zongertinib HER2 inhibitor | ERBB2 | Phase 3 | Lung Cancer, Non-squamous, Non-small Cell; Non-small Cell Lung Cancer; Solid Tumours; Healthy … | Dec 2026 |
| Sichuan Baili Pharmaceutical | BL-M07D1 anti-HER2 antibody-drug conjugate | ERBB2 | Phase 3 | HER2-low Breast Cancer; Gastric Adenocarcinoma; Non-squamous Non-small Cell Lung Cancer; HER2-positive Breast Cancer … | Dec 2026 |
| Jiangsu HengRui Medicine | Pyrotinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor | EGFR, ERBB2 | Phase 3 | Breast Cancer; Advanced Non-small Cell Lung Cancer; HER2-positive Breast Cancer; Metastatic Breast Cancer … | Dec 2026 |
| Suzhou Suncadia Biopharmaceuticals | SHR-A1811 for Injection HER2-targeted antibody-drug conjugate | ERBB2 | Phase 3 | Advanced Colorectal Cancer; PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer; Ovarian Cancer; Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma … | Dec 2026 |
| Fudan University | SHR-A1811 anti-HER2 antibody-drug conjugate | ERBB2 | Phase 3 | Breast Cancer; Advanced Salivary Gland Carcinoma; Triple-negative Breast Cancer; Pancreatic Cancer … | Dec 2026 |
| Jazz Pharmaceuticals | Zanidatamab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Gastric Neoplasms; Metastatic HER2-positive Breast Cancer; Biliary Tract Cancer; Breast Cancer … | Dec 2026 |
| Pfizer | trastuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Colorectal Neoplasms; Uterine Neoplasms; Anatomic Stage IV Breast Cancer AJCC v8; Elderly Females … | Dec 2026 |
| Pfizer | tucatinib Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | HER2 Positive Breast Cancer; Colorectal Neoplasms; HER2-positive Breast Cancer; Uterine Neoplasms … | Dec 2026 |
| Shanghai Miracogen | MRG002 anti-HER2 antibody-drug conjugate | ERBB2 | Phase 3 | Advanced or Metastatic Urothelium Cancer | Jan 2027 |
| Chia Tai Tianqing Pharmaceutical Group | TQB2102 for Injection HER2 antibody-drug conjugate | ERBB2 | Phase 3 | Breast Cancer | Jan 2027 |
| Roche | Pertuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Solid Tumors | Mar 2027 |
| Daiichi Sankyo | Trastuzumab Deruxtecan Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor | ERBB2, TOP1 | Phase 3 | Breast Cancer; Gastric Cancer, Adenocarcinoma; Advanced Cancer; Gastric Cancer … | Mar 2027 |
| Roche | Trastuzumab Emtansine Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor | ERBB2, Tubulin | Phase 3 | Breast Cancer; Ovarian Cancer; Metastatic Solid Tumor; Early Breast Cancer … | Mar 2027 |
| R-Pharm | RPH-051 HER2-directed monoclonal antibody | ERBB2 | Phase 3 | Locally Advanced Breast Cancer | May 2027 |
| Shanghai Henlius Biotech | HLX22 HER2-targeted monoclonal antibody | ERBB2 | Phase 3 | Gastroesophageal-junction Cancer; HER2-low Hormone Receptor Positive Breast Cancer; HER2 + Breast Cancer | Jun 2027 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB2930 injection Dual-epitope HER2 antibody targeting ECD2 and ECD4 epitopes | ERBB2 | Phase 3 | HER2-positive Advanced Breast Cancer; Colorectal Cancer; Advanced Solid Tumor | Jun 2027 |
| DualityBio | DB-1303/BNT323 HER2-targeting bispecific antibody | ERBB2 | Phase 3 | HER2-positive Breast Cancer; Metastatic Breast Cancer; HER2-positive Advanced Solid Tumor | Aug 2027 |
| Bayer | BAY 2927088 (Sevabertinib) MATE1 and MATE2-K transporter inhibitor | ERBB2, SLC47A1, SLC47A2 | Phase 3 | Advanced Non-small Cell Lung Cancer, HER2 Mutation; Advanced Solid Tumors; Healthy Participants | Oct 2027 |
| OSE Immunotherapeutics | OSE2101 peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an | TP53, ERBB2, CEA, MAGEA2, MAGEA3 | Phase 3 | Patients With Non-Small Cell Lung Cancer; Solid Advanced Tumor | Dec 2027 |
| Innovent Biologics (Suzhou) | IBI354 HER2-directed antibody-drug conjugate | ERBB2 | Phase 3 | Ovarian; Locally Advanced Unresectable or Metastatic Solid Tumors | Dec 2027 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 3 | Early-stage Breast Cancer | Feb 2028 |
| BioNTech SE | BNT323/DB-1303 anti-HER2 antibody-drug conjugate with topoisomerase I inhibitor payload | ERBB2 | Phase 3 | Endometrial Cancer | Mar 2028 |
| Innovent Biopharmaceutical Technology (Hangzhou) | IBI354 Anti-HER2 antibody | ERBB2 | Phase 3 | HER2-positive Breast Cancer | Apr 2028 |
| Region Skane | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 3 | Non-Small Cell Lung Cancer | Sep 2028 |
| Region Skane | Dacomitinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 3 | Non-Small Cell Lung Cancer | Sep 2028 |
| SystImmune | Trastuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Urothelial Cancer | Dec 2028 |
| Suzhou Suncadia Biopharmaceuticals | Trastuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Triple Negative Breast Cancer | Dec 2030 |
| Greenwich LifeSciences | GLSI-100 HER2/Neu peptide vaccine with GM-CSF adjuvant | ERBB2 | Phase 3 | Breast Cancer | Dec 2031 |
| Prof. Wolfgang Janni | Trastuzumab-Deruxtecan HER2-targeted antibody-drug conjugate (anti-HER2 ADC with topoisomerase I inhibitor payloa | ERBB2 | Phase 3 | Breast Cancer | Apr 2032 |
| SWOG Cancer Research Network | HER2-targeted Therapy HER2 receptor antagonist or antibody | ERBB2 | Phase 3 | Anatomic Stage IV Breast Cancer AJCC v8 | May 2032 |
| Biocad | Pertuzumab (BCD-178) Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Breast Cancer | – |
| Shanghai Henlius Biotech | Pertuzumab (HLX11) Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Breast Cancer; Elderly Females; Metastatic Breast Cancer; Invasive Breast Cancer … | – |
| BioRay Pharmaceutical | Trastuzumab (HS627) Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Breast Cancer | – |
| MedSIR | Trastuzumab-Deruxtecan HER2-directed antibody-drug conjugate with topoisomerase I inhibitor payload | ERBB2 | Phase 2 | Breast Cancer | Nov 2026 |
| RenJi Hospital | [18F]F-RESCA-RCCB6 Trop2/HER2-targeted PET imaging agent | CD70, TROP2, TACSTD2, ERBB2 | Phase 2 | Urologic Neoplasms; Renal Cancer; Solid Tumor; Breast Cancer | Nov 2026 |
| National University Hospital, Singapore | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | NSCLC | Dec 2026 |
| Yale University | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | HER2/Neu+ Uterine Serous Carcinoma | Dec 2026 |
| Ambrx | Anvatabart Opadotin (ARX788) Tubulin inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent | Tubulin, ERBB2 | Phase 2 | HER2 Positive Metastatic Breast Cancer; Breast Neoplasms; HER2-positive, Metastatic Breast Cancer; HER2-positive Breast Cancer … | Dec 2026 |
| Ruth O'Regan | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer | Dec 2026 |
| Fudan University | DV anti-HER2 antibody-drug conjugate | ERBB2 | Phase 2 | Renal Insufficiency | Dec 2026 |
| Tianjin Medical University Second Hospital | disitamab-vedotin (RC48) anti-HER2 antibody-drug conjugate | ERBB2 | Phase 2 | Neoadjuvant Immunotherapy | Dec 2026 |
| Abscint NV/SA | 68Ga-ABS011 single domain antibody (sdAb) targeting HER2 labeled with gallium-68 for PET imaging | ERBB2 | Phase 2 | Metastatic Breast Cancer | Dec 2026 |
| The First Affiliated Hospital with Nanjing Medical University | Disitamb Vedotin HER2-targeting antibody-drug conjugate | ERBB2 | Phase 2 | Breast Cancer | Dec 2026 |
| Shenyang Sunshine Pharmaceutical | SSGJ-705 Anti-PD-1 and anti-HER2 bispecific antibody | PDCD1, ERBB2 | Phase 2 | Locally Advanced, Recurrent or Metastatic Malignancies; Locally Advanced (Unresectable) or Metastatic Solid Tumors | Dec 2026 |
| Partner Therapeutics | Zenocutuzumab (MCLA-128) ErbB-2/ErbB-3 heterodimer inhibitor | ERBB2, ERBB3 | Phase 2 | Solid Tumours Harboring NRG1 Fusion | Dec 2026 |
| National Cancer Institute (NCI) | Afatinib Dimaleate Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Advanced Lymphoma | Jan 2027 |
| Aston Sci. | AST-301 (pNGVL3-hICD) Therapeutic cancer vaccine expressing human ICD (immunogenic cell death) | ERBB2 | Phase 2 | Gastric Cancer | Feb 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Squamous Cell Carcinoma | Feb 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | HER-2 pulsed DC1 HER2-directed dendritic cell vaccine | ERBB2 | Phase 2 | HER2-positive Breast Cancer | Feb 2027 |
| National Cancer Institute (NCI) | Neratinib Maleate Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Malignant Female Reproductive System Neoplasm; Metastatic Malignant Solid Neoplasm | Feb 2027 |
| Shanghai Zhongshan Hospital | HLX22 Anti-HER2 monoclonal antibody (dual HER2 blockade with trastuzumab) | ERBB2 | Phase 2 | Metastatic PDAC | Mar 2027 |
| Gangnam Severance Hospital | Herzuma anti-HER2 monoclonal antibody | ERBB2 | Phase 2 | HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study | Mar 2027 |
| National Cancer Centre, Singapore | Dacomitinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | NSCLC Stage IIIB; Advanced Solid Tumours | Apr 2027 |
| Latin American Cooperative Oncology Group | PHESGO HER2-targeting dual monoclonal antibody combination (pertuzumab and trastuzumab) | ERBB2 | Phase 2 | Breast Cancer | Apr 2027 |
| MedSIR | PHESGO (Pertuzumab-Trastuzumab fixed dose combination) Combination of anti-HER2 antibody (trastuzumab) and anti-HER2 dimerization inhibitor (pert | ERBB2 | Phase 2 | HER2-positive Breast Cancer | Apr 2027 |
| City of Hope Medical Center | Lapatinib ditosylate Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ERBB2, EGFR | Phase 2 | Breast Neoplasms | Apr 2027 |
| Shanghai Chest Hospital | Dacomitinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Non-small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer (NSCLC) | May 2027 |
| Criterium | Trastuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 2 | Breast Cancer | Jun 2027 |
| Shenyang Sunshine Pharmaceutical | SSGJ-612 HER2-targeting agent | ERBB2 | Phase 2 | Locally Advanced (Unresectable) or Metastatic Solid Tumors; Metastatic Breast Cancer; Advanced Malignant Tumors | Jun 2027 |
| Roche | Trastuzumab Emtansine Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor | ERBB2, Tubulin | Phase 2 | Neoplasm Metastasis | Jun 2027 |
| Dana-Farber Cancer Institute | Margetuximab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 2 | Breast Cancer | Jul 2027 |
| Chengdu SciMount Pharmatech | SMP-656 HER2-targeted antibody-drug conjugate (ADC) | ERBB2 | Phase 2 | HER2-positive Breast Cancer | Jul 2027 |
| University Health Network, Toronto | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer | Jul 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | Dendritic Cell Vaccine (DCV) Dendritic cell vaccine targeting HER2 | ERBB2 | Phase 2 | Breast Cancer Female; Leptomeningeal Disease | Aug 2027 |
| University of Texas Southwestern Medical Center | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Advanced Squamous Non Small Cell Lung Cancer | Sep 2027 |
| University of Rochester | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer | Sep 2027 |
| Centre Henri Becquerel | [68Ga]Ga-NOTA-anti-HER2-sdAb anti-HER2 single domain antibody PET/CT imaging agent | ERBB2 | Phase 2 | Breast Cancer | Sep 2027 |
| Fondazione Ricerca Traslazionale | Tedopi Cancer vaccine inducing cytotoxic T-lymphocytes against tumor-associated antigens (CEA, p5 | CEA, TP53, ERBB2, MAGE2, MAGE3 | Phase 2 | Metastatic Non Small Cell Lung Cancer | Sep 2027 |
| National Taiwan University Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | NSCLC Stage IV | Oct 2027 |
| Gruppo Oncologico del Nord-Ovest | Trastuzumab-Deruxtecan Anti-HER2 antibody-drug conjugate with DXd payload | ERBB2 | Phase 2 | Colorectal Cancer | Oct 2027 |
| Memorial Sloan Kettering Cancer Center | 89Zr-ss-pertuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 2 | Breast Cancer; HER-2 Positive Malignant Carcinoma of Breast | Nov 2027 |
| Massachusetts General Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Lung Cancer; Advanced Solid Tumor | Dec 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | WOKVAC pUMVC3-based vaccine targeting IGFBP2, HER2, and IGF1R | IGFBP2, ERBB2, IGF1R | Phase 2 | Breast Cancer Female | Dec 2027 |
| Shandong Public Health Clinical Center | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Carcinoma, Non-Small-Cell Lung | Dec 2027 |
| Henan Cancer Hospital | Inetetamab Anti-HER2 monoclonal antibody | ERBB2 | Phase 2 | Breast Neoplasms | Jan 2028 |
| Centre Leon Berard | Lapatinib Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ERBB2, EGFR | Phase 2 | Malignant Solid Neoplasms | Jan 2028 |
| David Reardon, MD | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Glioblastoma | Feb 2028 |
| Shenyang Sunshine Pharmaceutical | HER2-targeted ADC HER2-targeted antibody-drug conjugate | ERBB2 | Phase 2 | Metastatic Breast Cancer | Feb 2028 |
| H. Lee Moffitt Cancer Center and Research Institute | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | GastroEsophageal Cancer | Mar 2028 |
| Roswell Park Cancer Institute | Anti-HER2/HER3 Dendritic Cell Vaccine Dendritic cell vaccine targeting HER2 and HER3 | ERBB2, ERBB3 | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8 | May 2028 |
| Jiangsu HengRui Medicine | Trastuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 2 | Unresectable Locally Recurrent Breast Cancer | Jun 2028 |
| Seoul National University Hospital | Samfenet (Trastuzumab-biosimilar) HER2-targeted monoclonal antibody | ERBB2 | Phase 2 | Advanced Breast Cancer | Jun 2028 |
| Tianjin Medical University Cancer Institute and Hospital | SHR-A1811 Anti-HER2 antibody-drug conjugate | ERBB2 | Phase 2 | Advanced Breast Cancer With Ultra-Low HER2 Expression | Sep 2028 |
| Fudan University | SKB264 HER2-targeting antibody | ERBB2 | Phase 2 | HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer | Sep 2028 |
| Sichuan Baili Pharmaceutical | Pertuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 2 | HER2-positive Breast Cancer | Dec 2028 |
| Henan Cancer Hospital | SHR-A1811 anti-HER2 antibody-drug conjugate (ADC) | ERBB2 | Phase 2 | Metastatic Breast Cancer; Breast Cancer Early Stage Breast Cancer (Stage 1-3); HER2 Low Breast Carcinoma | Dec 2028 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Trastuzumab-rezetecan (SHR-A1811) HER2-targeted antibody-drug conjugate (ADC) | ERBB2 | Phase 2 | HER2-positive Early Breast Cancer | Dec 2028 |
| Henan Cancer Hospital | Patuzumab Anti-HER2 monoclonal antibody | ERBB2 | Phase 2 | Breast Cancer | Jun 2029 |
| Fudan University | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer With Brain Metastasis | Aug 2029 |
| Scott R. Plotkin, MD, PhD | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Neurofibromatosis Type 2 | Dec 2029 |
| Spanish Breast Cancer Research Group | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Early-stage Breast Cancer | Jan 2030 |
| Vanderbilt-Ingram Cancer Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Anatomic Stage I Breast Cancer | Apr 2030 |
| Dartmouth-Hitchcock Medical Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Advanced Breast Cancer | Oct 2030 |
| Pieris Pharmaceuticals | Cinrebafusp alfa (PRS-343) HER2/4-1BB bispecific antibody | ERBB2, TNFRSF9 | Phase 2 | HER2-positive Gastric Cancer | – |
| Baylor Breast Care Center | Lapatinib Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ERBB2, EGFR | Phase 2 | Breast Cancer | – |
| UNICANCER | Sapitinib (AZD8931) Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-3 inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ERBB2, ERBB3, EGFR | Phase 2 | Metastatic Breast Cancer | – |
| Anbogen Therapeutics | ABT-101 HER2 tyrosine kinase inhibitor | ERBB2 | Phase 1 | Advanced Solid Tumor | Nov 2026 |
| RenJi Hospital | [18F]F-RESCA-RB14 Trop2/HER2-targeted PET imaging agent | TACSTD2, ERBB2 | Phase 1 | Breast Cancer | Nov 2026 |
| AP Biosciences | AP402 HER2-targeting immunoconjugate | ERBB2 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Jeeyun Lee | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Stomach Neoplasm | Dec 2026 |
| ExpreS2ion Biotechnologies | ES2B-C001 HER2-expressing cancer vaccine | ERBB2 | Phase 1 | Breast Cancer | Dec 2026 |
| Iksuda Therapeutics | IKS014 anti-HER2 antibody-drug conjugate (MMAF payload) | ERBB2 | Phase 1 | Breast Cancer | Dec 2026 |
| Sunshine Guojian Pharmaceutical (Shanghai) | SSGJ-705 anti-PD-1 and anti-HER2 bispecific antibody | PDCD1, ERBB2 | Phase 1 | Locally Advanced, Recurrent or Metastatic Malignancies | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQB2930 for injection HER2 bispecific antibody | ERBB2 | Phase 1 | Metastatic Breast Cancer | Dec 2026 |
| Baylor College of Medicine | HER2-specific CAR VST (CAR T cells) HER2-directed chimeric antigen receptor T cells (cytotoxic T lymphocytes) | ERBB2 | Phase 1 | Bladder Cancer; Sarcoma; Brain Tumor, Recurrent | Dec 2026 |
| Shanghai Institute Of Biological Products | SIBP-A17 HER2-targeted antibody-drug conjugate (ADC) | ERBB2 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Chinese PLA General Hospital | HypoSti.CAR-HER2 T cells HER2-targeted CAR-T cells with hypoxia-stimulated CAR expression system | ERBB2 | Phase 1 | HER2 Positive Advanced Solid Tumors | Dec 2026 |
| Affibody | [177Lu]Lu-ABY-271 HER2-targeted Affibody fusion with lutetium-177 radioisotope | ERBB2 | Phase 1 | Metastatic Breast Cancer | Jan 2027 |
| Enliven Therapeutics | ELVN-002 HER2 kinase inhibitor | ERBB2 | Phase 1 | HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Breast Cancer | Jan 2027 |
| Nuvalent | NVL-330 HER2 tyrosine kinase inhibitor | ERBB2 | Phase 1 | Locally Advanced Solid Tumor | Jan 2027 |
| City of Hope Medical Center | HER2-CAR T cells HER2-targeted chimeric antigen receptor T-cell therapy | ERBB2 | Phase 1 | Malignant Neoplasm | Jan 2027 |
| Myeloid Therapeutics | MT-304 mRNA-LNP encoding HER2-targeted immunotherapy | ERBB2 | Phase 1 | HER2-Expressing Solid Tumors | Jan 2027 |
| Beijing Biotech | EB-G3B7-NK dual-target CAR-NK cells Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr | CD276, MSLN, EGFR, ERBB2, IL13RA2 | Phase 1 | Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) … | Feb 2027 |
| Beijing Biotech | EB-DT-CAR-NK Dual-target CLDN18.2/HER2 CAR-NK cells | CLDN18, ERBB2 | Phase 1 | Advanced Gastric Adenocarcinoma | Mar 2027 |
| Beijing Biotech | EB-DUO-CAR-NK-CEA/GCC Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H | CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15 | Phase 1 | Colorectal Cancer; Colorectal Cancer Metastatic | Mar 2027 |
| Beijing Biotech | EB-HC01 dual-target CAR-NK cells Allogeneic dual-target CAR-NK cells targeting HER2 and CEA/CEACAM5 | ERBB2, CEACAM5 | Phase 1 | Cholangiocarcinoma | Mar 2027 |
| Beijing Biotech | EBNK-1822H2 Dual-target CLDN18.2/HER2 CAR-NK cells | CLDN18A2, ERBB2 | Phase 1 | Recurrent or Metastatic Esophageal Adenocarcinoma | Mar 2027 |
| Beijing Biotech | EGFR/HER2 Dual-Target CAR-NK Cells Allogeneic donor-derived NK cells engineered to express dual EGFR/HER2 chimeric antigen re | EGFR, ERBB2 | Phase 1 | Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Mar 2027 |
| Roche | Runimotamab HER2-targeting bispecific antibody | ERBB2 | Phase 1 | Solid Tumors | Apr 2027 |
| National Cancer Institute (NCI) | Lapatinib Receptor protein-tyrosine kinase erbB-2 inhibitor; Epidermal growth factor receptor erbB1 inhibitor | ERBB2, EGFR | Phase 1 | Metastatic Thyroid Gland Carcinoma | May 2027 |
| Memorial Sloan Kettering Cancer Center | Rat HER2 DNA Xenogeneic HER2/neu DNA immunization | ERBB2 | Phase 1 | Breast Cancer | May 2027 |
| West China Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | HNSCC; Esophagus Cancer | May 2027 |
| Merck & Co. (MSD) | Infinatamab Deruxtecan (I-DXd, MK-2400) HER2-targeting antibody-drug conjugate | ERBB2 | Phase 1 | Oesophageal Squamous Cell Carcinoma; Small Cell Lung Cancer Extensive Stage; Esophageal Squamous Cell Carcinoma | Jun 2027 |
| Beijing Biotech | EB-DT-NK-UC101 Allogeneic dual-target Nectin-4/HER2 CAR-NK cells with inducible caspase-9 safety switch | NECTIN4, ERBB2 | Phase 1 | Bladder Cancer | Jun 2027 |
| Fox Chase Cancer Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Gastric Cancer | Jun 2027 |
| HighField Biopharmaceuticals | HF158K1 Liposomal doxorubicin with HER2-directed trastuzumab Fab fragment | ERBB2 | Phase 1 | Solid Tumors, Adult | Jun 2027 |
| CSPC Megalith Biopharmaceutical | SYS6045 HER2-targeted therapy | ERBB2 | Phase 1 | Advanced Solid Tumors | Jul 2027 |
| Memorial Sloan Kettering Cancer Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Solid Tumor | Oct 2027 |
| Virginia Commonwealth University | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Advanced Solid Tumor | Oct 2027 |
| Essen Biotech | CD146/HER2 CAR-T cells Dual CAR-T cells targeting CD146 and HER2 | MCAM, ERBB2 | Phase 1 | Sarcoma | Dec 2027 |
| Suzhou Biomissile Pharmaceuticals | BM230 HER2-targeting biotherapeutic | ERBB2 | Phase 1 | Solid Tumor | Dec 2027 |
| M.D. Anderson Cancer Center | Izalontamab Brengitecan Anti-HER2 antibody-drug conjugate | ERBB2 | Phase 1 | Non-small Cell Lung Cancer | Dec 2027 |
| Mayo Clinic | Multi-epitope HER2 Peptide Vaccine H2NVAC HER2-specific helper T-cell epitope vaccine | ERBB2 | Phase 1 | Breast Ductal Carcinoma In Situ | Dec 2027 |
| Johann Wolfgang Goethe University Hospital | NK-92/5.28.z HER2-targeted CAR-NK cell therapy | ERBB2 | Phase 1 | Glioblastoma | Dec 2027 |
| Yuhan | YH42946 Dual EGFR exon 20 insertion and HER2 inhibitor | EGFR, ERBB2 | Phase 1 | NSCLC (Non-small Cell Lung Cancer) | Mar 2028 |
| Yuhan | YH32367 HER2-targeted therapy | ERBB2 | Phase 1 | HER2-Positive Solid Tumor | Mar 2028 |
| Cogent Biosciences | CGT4255 Selective ERBB2 inhibitor | ERBB2 | Phase 1 | Advanced Solid Tumor, Adult | May 2028 |
| Baylor College of Medicine | HER2 CAR T cells anti-HER2 CAR T cell therapy | ERBB2 | Phase 1 | Sarcoma | Jun 2028 |
| HighField Biopharmaceuticals | HF50 Liposome-encapsulated bifunctional therapeutic; HER2-redirected T-cell engager with TLR7/8 | ERBB2, TLR7, TLR8 | Phase 1 | Advanced Solid Tumors | Jun 2028 |
| National University Hospital, Singapore | Epo-R-CD19 CAR T CAR-T cell therapy targeting CD19 and Epo-R expressing B cell lymphoma cells | ERBB2, CD19 | Phase 1 | B-cell Lymphoma Refractory | Oct 2028 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Fanconi Anemia | Dec 2028 |
| D3 Bio (Wuxi) | D3L-001 Anti-HER2 antibody | ERBB2 | Phase 1 | HER-2 Positive Advanced Solid Tumors | Dec 2028 |
| Fudan University | GQ1001 HER2-targeted antibody-drug conjugate | ERBB2 | Phase 1 | Advanced/ Metastatic Her-2 Positive Breast Cancer | Dec 2028 |
| Baylor College of Medicine | HTR2 T Cells TRAIL-R2 and HER2 bi-specific chimeric antigen receptor (CAR) T cells | TRAIL-R2, ERBB2 | Phase 1 | Breast Cancer | Jan 2029 |
| Fate Therapeutics | FT825 HER2-directed CAR-T cell therapy | ERBB2 | Phase 1 | Advanced Solid Tumor | May 2029 |
| BioNTech SE | BNT323 HER2-targeted antibody-drug conjugate (trastuzumab conjugated with panmitrimer) | ERBB2 | Phase 1 | Locally Advanced Breast Cancer | Aug 2029 |
| Pravin T.P Kaumaya | MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines HER2 peptide vaccine | ERBB2 | Phase 1 | Breast Cancer | Dec 2029 |
| Pravin T.P Kaumaya | MVF-HER-2 (597-626) and MVF-HER-2 (266-296) vaccine emulsified with ISA 51 HER-2 peptide vaccine targeting HER-2 epitopes; administered with Montanide ISA 51 adjuvan | ERBB2 | Phase 1 | Metastatic Breast Cancer | Dec 2029 |
| University of Virginia | HER2 BATs HER2-targeted bispecific activated T-cells | ERBB2 | Phase 1 | Metastatic Breast Cancer | Jan 2031 |
| Baylor College of Medicine | Autologous CAR Positive T cells HER2-specific chimeric antigen receptor (CAR) expressing T cells | ERBB2 | Phase 1 | Sarcoma | Jul 2032 |
| Children's Oncology Group | HER2 Specific CAR T Cell anti-HER2 CAR-T cell therapy | ERBB2 | Phase 1 | Ependymoma | Mar 2033 |
| Vironexis Biotherapeutics | VNX-202 Adeno-associated viral vector encoding CD3/HER2 bi-specific T-cell engager | CD3, ERBB2 | Phase 1 | HER2 Expressing Solid Tumors | Sep 2033 |
| Seattle Children's Hospital | HER2-specific chimeric antigen receptor (CAR) T cell HER2-specific CAR T cell therapy with EGFRt suicide gene | ERBB2 | Phase 1 | Central Nervous System Tumor, Pediatric | Jul 2039 |
| China Medical University Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Non-small Cell Lung Cancer | – |
Breast Cancer (116) HER2-positive Breast Cancer (42) Metastatic Breast Cancer (22) Gastric Cancer (16) Breast Neoplasms (12) HER2 + Breast Cancer (11) Advanced Solid Tumor (10) Ovarian Cancer (7) Non-small Cell Lung Cancer (7) Advanced Breast Cancer (7) HER2-positive Gastric Cancer (6) Biliary Tract Cancer (6)
mixed (62), small molecule (59), antibody (22), other (10), protein or peptide (5)
Beijing Biotech (7) Fudan University (6) H. Lee Moffitt Cancer Center and Research Institute (5) Roche (4) Baylor College of Medicine (4) National Cancer Institute (NCI) (3) Memorial Sloan Kettering Cancer Center (3) Henan Cancer Hospital (3) Jiangsu HengRui Medicine (3) Shenyang Sunshine Pharmaceutical (3) Suzhou Suncadia Biopharmaceuticals (2) Pfizer (2) Sichuan Baili Pharmaceutical (2) Shanghai Henlius Biotech (2) Pravin T.P Kaumaya (2) Region Skane (2) Chia Tai Tianqing Pharmaceutical Group (2) Yuhan (2) RenJi Hospital (2) National University Hospital, Singapore (2)
EGFR (42) ERBB4 (32) Tubulin (5) CEA (3) ERBB3 (3) TOP1 (2) PDCD1 (2) TACSTD2 (2) TP53 (2) CEACAM5 (2) CLDN18 (1) MCAM (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.